CSL Ltd Price, Chart & Factor Exposure
Free Data & Analytics AccessNext earnings: Tue, Feb 9, 2027 · estimates and history
CSL Ltd Forecast
CSL Ltd short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (7 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 16.2% a year, a typical one-standard-deviation range is 192.78–201.80 over a week, 188.05–206.53 over a month and 165.30–229.28 over a year. (Signals as of 21 Nov 2026.)
CSL Ltd Price Chart
CSL Ltd Factors
YoY +5.3%
YoY +42.4%
YoY +14.8%
YoY +4.4%
YoY +7.0%
YoY −120.4%
YoY −8.4%
YoY +8.6%
YoY −1.1%
YoY +5.5%
YoY −10.2%
YoY −13.1%
YoY −6.4%
YoY +22.7%
YoY −28.6%
YoY +10.4%
CSL Ltd fundamentals: income statement, balance sheet & cash flow
CSL Ltd reported revenue of 15.70bn AUD and net income of -2.58bn AUD in FY2026, the year ended 30 June 2026 — revenue up 1.7% and net income down 185.9% on the prior year. Free cash flow was 2.23bn AUD. These figures are as reported in the filings, not restated: 34 fiscal years and 130 quarters of history, back to June 1993.
| AUD billions | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | 30 Jun 2026 | 30 Jun 2025 | 30 Jun 2024 | 30 Jun 2023 | 30 Jun 2022 |
| Revenue | 15.70 | 15.43 | 14.69 | 13.17 | 10.49 |
| Cost of revenue | 8.21 | 7.48 | 7.13 | 6.47 | 4.83 |
| Gross profit | 7.49 | 7.95 | 7.56 | 6.71 | 5.66 |
| Research & development | 1.22 | 1.36 | 1.43 | 1.22 | 1.16 |
| Selling, general & admin. | — | 3.63 | 3.37 | 3.39 | 2.19 |
| Operating income | 4.01 | 2.96 | 2.76 | 2.10 | 2.32 |
| EBITDA | 5.05 | 5.09 | 4.77 | 3.92 | 3.46 |
| Interest expense | 0.43 | 0.39 | 0.48 | 0.44 | 0.16 |
| Pre-tax income | -4.09 | 3.72 | 3.38 | 2.66 | 2.78 |
| Income tax | -1.10 | 0.59 | 0.66 | 0.42 | 0.52 |
| Net income | -2.58 | 3.00 | 2.64 | 2.19 | 2.25 |
Download CSL Ltd fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.CSL.AU&statement=all&freq=a&format=csv&years=10
Figures in AUD, statements as filed. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic.
Research on CSL Ltd
Explore MacroFinance macro & markets research and analysis.
CSL Ltd Trading Strategies
31 backtested tactical asset allocation strategies hold EFA (developed markets outside the US), the closest tradable exposure to CSL Ltd; 22 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in EFA | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Butler's Elastic Asset Allocation - Defensive | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Butler's Elastic Asset Allocation - Offensive | Aggressive | Monthly | Premium · upgrade to view | |||
| Momentum Turning Points | Conservative | Monthly | Premium · upgrade to view | |||
| Keller, Butler and Kipnis' Classical Asset Allocation - Offensive | Moderate | Monthly | Premium · upgrade to view | |||
| Financial Mentor's All-Weather Quad Momentum | Aggressive | Monthly | Premium · upgrade to view | |||
| Keller, Butler and Kipnis' Classical Asset Allocation - Defensive | Moderate | Monthly | Premium · upgrade to view | |||
| Livingston's Mama Bear (Muscular Portfolios) | Aggressive | Monthly | Premium · upgrade to view | |||
| Meb Faber's Global Tactical Asset Allocation 13 (GTAA 13) | Conservative | Monthly | Premium · upgrade to view | |||
| David Varadi's Minimum Correlation Portfolio | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
Statistical Distribution of Returns
PlusHow CSL Ltd’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About CSL Ltd (Australia)
CSL Ltd is a listed security in Australia. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
More on Carlisle Companies Incorporated
Frequently asked questions
What is CSL Ltd?
What is the latest CSL Ltd price?
Is CSL Ltd in an uptrend?
How volatile is CSL Ltd?
What factors affect CSL Ltd?
Which trading strategies trade CSL Ltd?
How are CSL Ltd returns analysed?
Where can I download free CSL Ltd historical data?
Free CSL Ltd historical data (last 10 years)
Browse or instantly download the last 10 years of CSL Ltd daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.CSL.AU&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 197.29 |
| 2026-11-19 | 199.85 |
| 2026-11-18 | 199.38 |
| 2026-11-17 | 199.55 |
| 2026-11-16 | 202.52 |
| 2026-11-13 | 202.92 |
| 2026-11-12 | 204.54 |
| 2026-11-11 | 201.68 |
| 2026-11-10 | 200.73 |
| 2026-11-09 | 200.77 |
About this stock
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company's therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery; and Alentis Therapeutics AG to develop and commercialise lixudebart for rare kidney and liver diseases. The company was formerly known as Commonwealth Serum Laboratories Limited and later changed its name to CSL Limited in October 1991. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.